Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 12;13(1):6016.
doi: 10.1038/s41467-022-33761-4.

Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine

Affiliations

Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine

Kai-Bo Wang et al. Nat Commun. .

Abstract

KRAS is one of the most highly mutated oncoproteins, which is overexpressed in various human cancers and implicated in poor survival. The G-quadruplex formed in KRAS oncogene promoter (KRAS-G4) is a transcriptional modulator and amenable to small molecule targeting. However, no available KRAS-G4-ligand complex structure has yet been determined, which seriously hinders the structure-based rational design of KRAS-G4 targeting drugs. In this study, we report the NMR solution structures of a bulge-containing KRAS-G4 bound to berberine and coptisine, respectively. The determined complex structure shows a 2:1 binding stoichiometry with each compound recruiting the adjacent flacking adenine residue to form a "quasi-triad plane" that stacks over the two external G-tetrads. The binding involves both π-stacking and electrostatic interactions. Moreover, berberine and coptisine significantly lowered the KRAS mRNA levels in cancer cells. Our study thus provides molecular details of ligand interactions with KRAS-G4 and is beneficial for the design of specific KRAS-G4-interactive drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no Competing interests.

Figures

Fig. 1
Fig. 1. KRAS-G4 and its interaction with berberine and coptisine.
a Schematic of the human KRAS gene promoter and the formation of a KRAS-G4 as well as its complex with small molecules (ligands). The G4-forming region of the NHE sequence is shown. The G-tracts implicated in KRAS-G4 formation are marked in red and mutations in cyan, respectively. b Chemical structures of berberine and coptisine with numbering. c 1D 1H NMR titration of Pu24m1 DNA with berberine and coptisine, respectively, with complete imino proton assignment. Conditions: 150 μM DNA, pH 7, 50 mM K+ solution, 25 °C, DMSO-d6 < 1.5%.
Fig. 2
Fig. 2. Biophysical characterization of berberine and coptisine binding to the KRAS-G4.
a CD thermal melting curves and CD spectra of Pu24m1 DNA with berberine and coptisine, respectively. Conditions: 20 μM DNA, pH 7, 15 mM K+ solution. b Fluorescence intensity change of berberine and coptisine upon titration with Pu24m1 DNA, respectively. Conditions: 0.2 μM compound, pH 7, 50 mM K+ solution. c The determined ΔTm and Kd values of berberine and coptisine to the Pu24m1 DNA. The melting temperature (Tm) was obtained at the intersection between the median of the fitted baselines and the melting curve. The dissociation constant (Kd) was calculated by data fitting with a 2:1 binding equation. The experiments were run in duplicate.
Fig. 3
Fig. 3. 2D NMR spectra of the free KRAS-G4.
a The H1–H1 and H1–H8 regions, and b H1′-H6/H8 region from the 2D-NOESY spectra of Pu24m1 DNA in H2O with sequential assignment pathway. Missing connectivity is marked with red asterisks. The cross-peak assigned to the minor species is labeled in blue. c H6 − C6/H8−C8 cross-peaks of all bases (black label) and the adenine H2-C2 contacts (red label) with assignments for the Pu24m1 DNA by HSQC experiments. d The assigned three G-tetrad planes of KRAS-G4 by NMR experiments. Conditions: 1.5 mM DNA, pH 7, 50 mM K+ solution, 25 °C, DMSO-d6 < 3.5%.
Fig. 4
Fig. 4. NMR solution structures of KRAS-G4 and its complexes with berberine and coptisine.
Superposition of the ten lowest energy NMR structures of the free KRAS-G4 (a), berberine-KRAS-G4 (b), and coptisine-KRAS-G4 (c) by NOE-restrained structure calculations. Yellow, berberine; green, coptisine; cyan, flanking guanine; gray, tetrad guanine; magenta, adenine; blue, thymine; orange, cytosine.
Fig. 5
Fig. 5. Solution structure details of KRAS-G4 and its complexes with berberine and coptisine.
Cartoon representation and 5′-end and 3′-end top views of the free KRAS-G4 (a), the berberine-KRAS-G4 (b), and the coptisine-KRAS-G4 (c) complexes (Protein Data Bank IDs: 7X8N, 7X8M, and 7X8O). Yellow, berberine; green, coptisine; cyan, flanking guanine; gray, tetrad guanine; magenta, adenine; blue, thymine; orange, cytosine. Potential hydrogen bonds are shown as dashed lines.
Fig. 6
Fig. 6. 2D NMR spectra of KRAS–G4 in complex with berberine and coptisine.
Select regions of the 2D-NOESY spectra of 3:1 berberine-KRAS-G4 (a) and 2.5 :1 coptisine-KRAS-G4 (b) complexes in H2O showing intermolecular cross-peaks between compound and DNA imino protons. Conditions: 1.5 mM Pu24m1 DNA, pH 7, 50 mM K+ solution, 35 °C, DMSO-d6 < 3.5%.
Fig. 7
Fig. 7. Functional characterization of KRAS-G4.
a Taq DNA polymerase stop assay using a DNA template containing a wt human KRAS-G4 forming sequence shows that berberine and coptisine can stabilize the KRAS-G4 for replication inhibition. b qRT-PCR results show that berberine (24 µM) and coptisine (10 µM) lower KRAS mRNA levels in both H460 and A549 cancer cells for 24 h. DMSO (<0.1 %) was used as the negative control (no inhibition, 100%). The relative KRAS mRNA levels were normalized with GAPDH. The experiments were run in triplicate. Data are presented as mean values ± SD. P values (**P < 0.01, ***P < 0.001, ****P < 0.0001) were determined by one-way ANOVA with post hoc Dunnett, relative to DMSO control.
Fig. 8
Fig. 8. Suggested modifications of berberine enabling additional interaction with the KRAS-G4.
The black circles indicate the positions to be modified by introducing side chains for groove interactions. The black arrows show the grooves at 5′- and 3′-sites where the attached side chain will locate. The red circle suggests the positions to introduce hydrogen bonds between berberine and thymine T10. The KRAS-G4 is shown in cartoon representation. Cyan, guanine; magenta, adenine; blue, thymine; orange, cytosine; yellow, berberine.

Similar articles

Cited by

References

    1. Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat. Rev. Drug Discov. 2020;19:533–552. doi: 10.1038/s41573-020-0068-6. - DOI - PMC - PubMed
    1. Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 2020;17:153–168. doi: 10.1038/s41575-019-0245-4. - DOI - PubMed
    1. Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann. Oncol. 2021;32:1101–1110. doi: 10.1016/j.annonc.2021.06.001. - DOI - PubMed
    1. Kim D, Xue JY, Lito P. Targeting KRAS(G12C): from inhibitory mechanism to modulation of antitumor effects in patients. Cell. 2020;183:850–859. doi: 10.1016/j.cell.2020.09.044. - DOI - PMC - PubMed
    1. Chen K, Zhang Y, Qian L, Wang P. Emerging strategies to target RAS signaling in human cancer therapy. J. Hematol. Oncol. 2021;14:116. doi: 10.1186/s13045-021-01127-w. - DOI - PMC - PubMed

Publication types